Abstract

COMPREHENSIVE REVIEW ON THE PHARMACOLOGICAL USE, SAFETY, AND CLINICAL EFFICACY OF MIFEPRISTONE AND MISOPROSTOL IN MEDICAL ABORTION

P. Kesavan*, P. Nandhitha, C. Jothimanivannan, P. Jothiprakash and R. Vimal and P. Boopathi

.

Abstract

Medical abortion is commonly performed at different stages of pregnancy using the antiprogestin mifepristone in conjunction with the prostaglandin analogue misoprostol. This routine is widely acknowledged and quite successful, particularly in the early stages of pregnancy. The usual procedure is to administer 800 mcg of misoprostol, usually sublingually or vaginally, after 200 mg of mifepristone. With a low frequency of major problems, the safety profile is still robust despite minor side effects including nausea and bleeding. This study focuses on the drug interactions, clinical results, complication rates, animal and human safety data, optimal regimens, and mechanism of action. Risk reduction requires appropriate supervision and emergency care access, particularly in isolated locations.

Keywords: Mifepristone, misoprostol, early pregnancy termination, progesterone antagonist, prostaglandin analog, pharmacological activities.